Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology
Clinical Trials: Peritoneal Cancer
A listing of clinical trials currently looking for volunteers to enroll in Peritoneal Cancer studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : University of Alabama at Birmingham
ChemoFx® PRO - A Post-Market Data Collection Study
Mobile : USA Mitchell Cancer Institute
ChemoFx® PRO - A Post-Market Data Collection Study
Arizona
Glendale : Arizona Center for Cancer Care Updated
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
Phoenix : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Scottsdale : Pinnacle Oncology Updated
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
Tucson : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
California
Bakersfield : Comprehensive Blood and Cancer Center Updated
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
Corona : Wilshire Oncology Medical Group Updated
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
Corona : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Los Gatos : Bay Area Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Oceanside : North County Oncology Updated
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
View More »
Oxnard : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Rancho Mirage : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
San Francisco : University of California San Francisco
ChemoFx® PRO - A Post-Market Data Collection Study
San Jose : San Jose Women's Medical Group
ChemoFx® PRO - A Post-Market Data Collection Study
Santa Maria : Central Coast Medical Oncology Updated
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
Sherman Oaks : Women's Cancer Center Sherman Oaks
ChemoFx® PRO - A Post-Market Data Collection Study
Torrance : GOA Torrance Memorial
ChemoFx® PRO - A Post-Market Data Collection Study
Florida
Boca Raton : South Florida Center for Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Clearwater : West Coast Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Delray Beach : Comprehensive Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Fort Lauderdale : Caruso and Gates MDs PA
ChemoFx® PRO - A Post-Market Data Collection Study
Fort Myers : Florida Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
View More »
Hollywood : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Pembroke Pines : Gynecologic Oncology Associates
ChemoFx® PRO - A Post-Market Data Collection Study
Sarasota : Sarasota Memorial Hospital
ChemoFx® PRO - A Post-Market Data Collection Study
South Miami : South Miami Gynecologic Oncology Group
ChemoFx® PRO - A Post-Market Data Collection Study
West Palm Beach : Palm Beach Cancer Institute
ChemoFx® PRO - A Post-Market Data Collection Study
Georgia
Savannah : Memorial Health University Medical Center
ChemoFx® Observational Study in Gynecological Solid Tumors
View More »
Riverdale : Southeastern Gynecologic Oncology, LLC
ChemoFx® PRO - A Post-Market Data Collection Study
Savannah : Memorial Health University Medical Center
ChemoFx® PRO - A Post-Market Data Collection Study
Hawaii
Honolulu : The Queens' Medical Center
ChemoFx® PRO - A Post-Market Data Collection Study
Illinois
Chicago : Rush University
ChemoFx® PRO - A Post-Market Data Collection Study
Evanston : NorthShore Medical Group
ChemoFx® PRO - A Post-Market Data Collection Study
Indiana
Indianapolis : Indiana University Simon Cancer Center Updated
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
Indianapolis : Indiana University
ChemoFx® PRO - A Post-Market Data Collection Study
Louisiana
Covington : Women's Cancer Center
ChemoFx® PRO - A Post-Market Data Collection Study
Shreveport : CHRISTUS Schumpert Health System
ChemoFx® PRO - A Post-Market Data Collection Study
Maryland
Baltimore : Sinai Hospital
ChemoFx® PRO - A Post-Market Data Collection Study
Silver Springs : Women's Health Specialists
ChemoFx® PRO - A Post-Market Data Collection Study
Massachusetts
Boston : Dana-Farber Cancer Institute
Vorinostat, Carboplatin and Gemcitabine Plus Vorinostat Maintenance in Women With Recurrent, Platinum-Sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Boston : Massachusetts General Hospital
Vorinostat, Carboplatin and Gemcitabine Plus Vorinostat Maintenance in Women With Recurrent, Platinum-Sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Worcester : UMass Memorial Hospital
ChemoFx® PRO - A Post-Market Data Collection Study
Michigan
Detroit : Henry Ford Health System
ChemoFx® PRO - A Post-Market Data Collection Study
Detroit : Karmanos Cancer Institute
ChemoFx® PRO - A Post-Market Data Collection Study
Grand Rapids : Gynecologic Oncology of West Michigan
ChemoFx® PRO - A Post-Market Data Collection Study
Mississippi
Jackson : Mississippi Oncology Associates
ChemoFx® PRO - A Post-Market Data Collection Study
New Jersey
Teaneck : Gara M Sommers MD
ChemoFx® PRO - A Post-Market Data Collection Study
Voorhees : Cooper Health System
ChemoFx® PRO - A Post-Market Data Collection Study
New York
Albany : Women's Cancer Care Associates
ChemoFx® PRO - A Post-Market Data Collection Study
Atlantic Beach : St. John's Episcopal Hospital
ChemoFx® PRO - A Post-Market Data Collection Study
Bronx : Montefiore Medical Center
ChemoFx® PRO - A Post-Market Data Collection Study
Buffalo : Roswell Park Cancer Institute
ChemoFx® PRO - A Post-Market Data Collection Study
Manhassett : North Shore LIJ Health System
ChemoFx® PRO - A Post-Market Data Collection Study
View More »
Mineola : Winthrop University Hospital
Phase 1-2 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
New York : Memorial Sloan-Kettering Cancer Center
Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab
North Carolina
Asheville : Hope: A Women's Cancer Center
ChemoFx® PRO - A Post-Market Data Collection Study
Charlotte : Carolinas Medical Center/Blumenthal Cancer Center Updated
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
Charlotte : Blumenthal Cancer Center
ChemoFx® PRO - A Post-Market Data Collection Study
Charlotte : Presbyterian Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Durham : Duke University Medical Center
ChemoFx® PRO - A Post-Market Data Collection Study
View More »
Wilmington : North Hanover Regional Medical Center
ChemoFx® PRO - A Post-Market Data Collection Study
Winston Salem : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Ohio
Cincinnati : University of Cincinnati
ChemoFx® PRO - A Post-Market Data Collection Study
Columbus : OSU Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Toledo : ProMedica Health System, Inc. Updated
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
Oklahoma
Oklahoma City : Oklahoma Gynecologic Oncology Group
ChemoFx® PRO - A Post-Market Data Collection Study
Oregon
Portland : Oregon Health & Science University
ChemoFx® PRO - A Post-Market Data Collection Study
Pennsylvania
Philadelphia : Fox Chase Cancer Center
MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
Pittsburgh : Pittsburgh Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Pittsburgh : Magee-Womens Hospital of UPMC
Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer
South Dakota
Sioux Falls : Sandford USD Health System
ChemoFx® PRO - A Post-Market Data Collection Study
Tennessee
Chattanooga : Chattanooga GYN Oncology Updated
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
Chattanooga : Chattanooga's Program in Women's Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Chattanooga : Chattanooga Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Knoxville : Thomas W. McDonald MD
ChemoFx® PRO - A Post-Market Data Collection Study
Texas
Austin : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Bedford : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Dallas : North Texas Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Dallas : Mary Crowley Cancer Research Center
Phase 1-2 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
Dallas : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
View More »
Ft. Sam Houston : Brooke Army Medical Center
ChemoFx® PRO - A Post-Market Data Collection Study
Houston : The University of Texas MD Anderson Cancer Center
MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
San Antonio : South Texas Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
San Antonio : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Utah
Ogden : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Virginia
Annandale : North Virigina Pelvic Surgery Associates
ChemoFx® PRO - A Post-Market Data Collection Study
Roanoke : Carilion Clinic Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Woodbridge : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
West Virginia
Morgantown : Mohammed Ashraf MD
ChemoFx® PRO - A Post-Market Data Collection Study
Wisconsin
West Allis : Aurora West Allis Medical Center
ChemoFx® PRO - A Post-Market Data Collection Study
Austria
Innsbruck : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Belgium
Bonheiden : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Charleroi : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Edegem : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Gent : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Hasselt : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
View More »
Kortrijk : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Leuven : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Liège : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Libramont : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Namur : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Oostende : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Sint-Niklaas : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Turnhout : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Wilrijk : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Canada
Sault Ste. Marie : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Denmark
Herlev : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
København Ø : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Roskilde : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Greece
Athens : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Thessaloniki : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Hong Kong
Hong Kong : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Italy
Brescia : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Milano : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Napoli : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Pisa : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Roma : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Japan
Kure-city : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Morioka-city : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Sapporo-city : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Korea, Republic of
Gyeonggi-do : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Seoul : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Netherlands
Leiden : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Spain
Badalona : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Barcelona : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Madrid : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Palma de Mallorca : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Valencia : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
View More »
Zaragoza : Research Site Updated
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
